What Is Tirzepatide?
Tirzepatide (brand names Mounjaro for diabetes, Zepbound for weight loss) is a dual GIP/GLP-1 receptor agonist medication approved by the FDA for treating type 2 diabetes and obesity. It works by mimicking two naturally occurring hormones that regulate blood sugar, appetite, and metabolism. Tirzepatide has shown remarkable efficacy in both glycemic control and weight reduction, with clinical trials demonstrating average weight loss of 15-22% of body weight.
FDA-Approved Dosing Schedule
Tirzepatide dosing follows a structured titration schedule to minimize gastrointestinal side effects while achieving therapeutic efficacy. The medication is administered as a once-weekly subcutaneous injection.
Starting Dose: 2.5 mg once weekly for 4 weeks
Increase #1: 5 mg once weekly for 4+ weeks
Increase #2: 7.5 mg once weekly for 4+ weeks (if needed)
Increase #3: 10 mg once weekly for 4+ weeks (if needed)
Increase #4: 12.5 mg once weekly for 4+ weeks (if needed)
Maximum Dose: 15 mg once weekly
Each dose increase occurs in 2.5 mg increments at 4-week intervals minimum
Dosing for Type 2 Diabetes (Mounjaro)
For type 2 diabetes management, tirzepatide demonstrates superior HbA1c reduction compared to other GLP-1 agonists. Dosing considerations for diabetes treatment:
- Initial Dose: 2.5 mg weekly is not therapeutic; it is a tolerability dose only
- Therapeutic Range: 5 mg to 15 mg once weekly
- Target HbA1c: Most patients achieve HbA1c under 7% at 10-15 mg doses
- Fasting Glucose: Typically reduces fasting blood glucose by 50-80 mg/dL
- Combination Therapy: Can be used with metformin, SGLT2 inhibitors; insulin dosing may need reduction
Dosing for Weight Management (Zepbound)
For chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions, tirzepatide follows the same titration schedule but focuses on weight loss outcomes:
- 5 mg dose: Average 15% total body weight loss
- 10 mg dose: Average 20% total body weight loss
- 15 mg dose: Average 22.5% total body weight loss
- Plateau Management: If weight loss plateaus for 3+ months, dose escalation may be appropriate
- Maintenance: Continue at effective dose; weight regain common if discontinued
Administration Guidelines
Proper injection technique ensures optimal absorption and reduces side effects:
- Injection Sites: Abdomen (preferred), thigh, or upper arm; rotate sites weekly
- Timing: Inject once weekly on the same day each week; time of day does not matter
- Storage: Refrigerate unused pens at 36-46°F (2-8°C); do not freeze
- Preparation: Allow pen to reach room temperature before injection (15-30 minutes)
- Missed Dose: If less than 4 days late, inject as soon as remembered; if more than 4 days late, skip and resume on regular schedule
Common Side Effects and Management
Gastrointestinal side effects are most common, especially during dose escalation. Most side effects are mild-to-moderate and decrease over time:
| Side Effect | Frequency | Management Strategy |
|---|---|---|
| Nausea | 20-30% | Eat smaller meals, avoid fatty foods, stay hydrated |
| Diarrhea | 15-20% | Increase fiber gradually, stay hydrated, avoid trigger foods |
| Constipation | 10-15% | Increase water and fiber intake, exercise regularly |
| Decreased appetite | 30-40% | Ensure adequate protein intake, eat nutrient-dense foods |
| Injection site reactions | 5-10% | Rotate injection sites, apply ice after injection |
Contraindications and Warnings
Tirzepatide is not appropriate for everyone. Absolute and relative contraindications include:
- Black Box Warning: Risk of thyroid C-cell tumors; not for patients with personal/family history of medullary thyroid carcinoma or MEN 2 syndrome
- Pancreatitis History: Contraindicated in patients with history of pancreatitis
- Severe GI Disease: Caution in gastroparesis, inflammatory bowel disease
- Pregnancy: Discontinue at least 2 months before planned pregnancy
- Renal Impairment: Use caution; dehydration from GI side effects can worsen kidney function
- Retinopathy: Rapid glucose reduction may temporarily worsen diabetic retinopathy
Cost and Insurance Coverage
Tirzepatide is expensive without insurance, though coverage is expanding:
- List Price: Approximately $1,000-$1,200 per month (4-5 pens)
- Mounjaro Savings Card: May reduce copay to $25/month for commercially insured patients
- Zepbound Savings: Similar copay assistance available for weight loss indication
- Medicare Coverage: Covers Mounjaro for diabetes but generally not Zepbound for weight loss
- Commercial Insurance: Increasing coverage for both indications; prior authorization often required
This calculator helps patients and providers understand the titration schedule and dosing progression for tirzepatide therapy. Always follow your healthcare provider's specific dosing instructions, as individual needs may vary.